Global Cancer Drug Therapy

Cancer Drug Therapy Comprehensive Study by Type (Targeted Therapy, Chemotherapy, Immunotherapy), Application (Angiogenesis Inhibitors, MTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)), End User (Hospitals, Clinics, Other End Users), Cancer (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer, Other Cancer Types) Players and Region - Global Market Outlook to 2028

Cancer Drug Therapy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The renal cancer drug therapy market has witnessed a dramatic change in its treatment paradigm over the last three decades. Although there are a variety of treatment options available, innovators have now shifted their focus towards more targeted therapies and immunotherapies. The market is primarily driven by lifestyle affecting factors such as reduced physical activity, excessive smoking and drinking. A rising aging population and the mounting prevalence of kidney cancer cases are some of the additional factors boosting the growth of the market. Strong pipeline and fast-emerging treatments are expected to further boost the market during the analysis period. However, high cost of drugs, looming off-patents and uncertain reimbursement policies are some of the factors that are likely to restrain the market growth.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAmgen / Allergan (United States), Argos Therapeutics (Netherlands), AstraZeneca (United Kingdom), Aveo Pharmaceuticals (United States), Bayer (Germany), Exelixis (United States), Incyte (United States), Merck (United States), Roche (Switzerland) and Bristol-Myers Squibb (United States)


This growth is primarily driven by Rising prevalence of cancer and autoimmune & infectious diseases and Launch of several diagnostic and screening programs worldwide.

Globally, a noticeable market trend is evident Increasing adoption of immunotherapy drugs over conventional treatment regimens Major Players, such as Amgen / Allergan (United States), Argos Therapeutics (Netherlands), AstraZeneca (United Kingdom), Aveo Pharmaceuticals (United States), Bayer (Germany), Exelixis (United States), Incyte (United States), Merck (United States), Roche (Switzerland) and Bristol-Myers Squibb (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Developments in the Market:
In December 2021, Allergan Aesthetics Completes Acquisition of Soliton. The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include a proven treatment for the appearance of cellulite. At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products
In July 2019, Amgen NA allergen launched Mvasi and Kanjinti, the first anticancer Biosimilar, in the united states. According to the Amgen-Allergan partnership, the list price of both products will be 15% lower than their respective reference products.

Influencing Trend:
Increasing adoption of immunotherapy drugs over conventional treatment regimens

Market Growth Drivers:
Rising prevalence of cancer and autoimmune & infectious diseases and Launch of several diagnostic and screening programs worldwide

Challenges:
Lack of awareness

Restraints:
Timeline issues, side-effects, and manufacturing complexities

Opportunities:
Increased demand for personalized medicines

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Cancer Drug Therapy Market
- Analysis about New Entrants in Cancer Drug Therapy Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Cancer Drug Therapy Study Sheds Light on
— The Cancer Drug Therapy Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Cancer Drug Therapy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cancer Drug Therapy industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
By Application
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Monoclonal Antibodies
  • Cytokine Immunotherapy (IL-2)
By End User
  • Hospitals
  • Clinics
  • Other End Users

By Cancer
  • Blood Cancer
  • Breast Cancer
  • Prostate Cancer
  • Gastrointestinal Cancer
  • Gynecologic Cancer
  • Respiratory/Lung Cancer
  • Other Cancer Types

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of cancer and autoimmune & infectious diseases
      • 3.2.2. Launch of several diagnostic and screening programs worldwide
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness
    • 3.4. Market Trends
      • 3.4.1. Increasing adoption of immunotherapy drugs over conventional treatment regimens
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Drug Therapy, by Type, Application, End User, Cancer and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Drug Therapy (Value)
      • 5.2.1. Global Cancer Drug Therapy by: Type (Value)
        • 5.2.1.1. Targeted Therapy
        • 5.2.1.2. Chemotherapy
        • 5.2.1.3. Immunotherapy
      • 5.2.2. Global Cancer Drug Therapy by: Application (Value)
        • 5.2.2.1. Angiogenesis Inhibitors
        • 5.2.2.2. MTOR Inhibitors
        • 5.2.2.3. Monoclonal Antibodies
        • 5.2.2.4. Cytokine Immunotherapy (IL-2)
      • 5.2.3. Global Cancer Drug Therapy by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Other End Users
      • 5.2.4. Global Cancer Drug Therapy by: Cancer (Value)
        • 5.2.4.1. Blood Cancer
        • 5.2.4.2. Breast Cancer
        • 5.2.4.3. Prostate Cancer
        • 5.2.4.4. Gastrointestinal Cancer
        • 5.2.4.5. Gynecologic Cancer
        • 5.2.4.6. Respiratory/Lung Cancer
        • 5.2.4.7. Other Cancer Types
      • 5.2.5. Global Cancer Drug Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cancer Drug Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen / Allergan (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Argos Therapeutics (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aveo Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Exelixis (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Incyte (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Drug Therapy Sale, by Type, Application, End User, Cancer and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Drug Therapy (Value)
      • 7.2.1. Global Cancer Drug Therapy by: Type (Value)
        • 7.2.1.1. Targeted Therapy
        • 7.2.1.2. Chemotherapy
        • 7.2.1.3. Immunotherapy
      • 7.2.2. Global Cancer Drug Therapy by: Application (Value)
        • 7.2.2.1. Angiogenesis Inhibitors
        • 7.2.2.2. MTOR Inhibitors
        • 7.2.2.3. Monoclonal Antibodies
        • 7.2.2.4. Cytokine Immunotherapy (IL-2)
      • 7.2.3. Global Cancer Drug Therapy by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Other End Users
      • 7.2.4. Global Cancer Drug Therapy by: Cancer (Value)
        • 7.2.4.1. Blood Cancer
        • 7.2.4.2. Breast Cancer
        • 7.2.4.3. Prostate Cancer
        • 7.2.4.4. Gastrointestinal Cancer
        • 7.2.4.5. Gynecologic Cancer
        • 7.2.4.6. Respiratory/Lung Cancer
        • 7.2.4.7. Other Cancer Types
      • 7.2.5. Global Cancer Drug Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Drug Therapy: by Type(USD Million)
  • Table 2. Cancer Drug Therapy Targeted Therapy , by Region USD Million (2017-2022)
  • Table 3. Cancer Drug Therapy Chemotherapy , by Region USD Million (2017-2022)
  • Table 4. Cancer Drug Therapy Immunotherapy , by Region USD Million (2017-2022)
  • Table 5. Cancer Drug Therapy: by Application(USD Million)
  • Table 6. Cancer Drug Therapy Angiogenesis Inhibitors , by Region USD Million (2017-2022)
  • Table 7. Cancer Drug Therapy MTOR Inhibitors , by Region USD Million (2017-2022)
  • Table 8. Cancer Drug Therapy Monoclonal Antibodies , by Region USD Million (2017-2022)
  • Table 9. Cancer Drug Therapy Cytokine Immunotherapy (IL-2) , by Region USD Million (2017-2022)
  • Table 10. Cancer Drug Therapy: by End User(USD Million)
  • Table 11. Cancer Drug Therapy Hospitals , by Region USD Million (2017-2022)
  • Table 12. Cancer Drug Therapy Clinics , by Region USD Million (2017-2022)
  • Table 13. Cancer Drug Therapy Other End Users , by Region USD Million (2017-2022)
  • Table 14. Cancer Drug Therapy: by Cancer(USD Million)
  • Table 15. Cancer Drug Therapy Blood Cancer , by Region USD Million (2017-2022)
  • Table 16. Cancer Drug Therapy Breast Cancer , by Region USD Million (2017-2022)
  • Table 17. Cancer Drug Therapy Prostate Cancer , by Region USD Million (2017-2022)
  • Table 18. Cancer Drug Therapy Gastrointestinal Cancer , by Region USD Million (2017-2022)
  • Table 19. Cancer Drug Therapy Gynecologic Cancer , by Region USD Million (2017-2022)
  • Table 20. Cancer Drug Therapy Respiratory/Lung Cancer , by Region USD Million (2017-2022)
  • Table 21. Cancer Drug Therapy Other Cancer Types , by Region USD Million (2017-2022)
  • Table 22. South America Cancer Drug Therapy, by Country USD Million (2017-2022)
  • Table 23. South America Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 24. South America Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 25. South America Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 26. South America Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 27. Brazil Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 28. Brazil Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 29. Brazil Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 30. Brazil Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 31. Argentina Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 32. Argentina Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 33. Argentina Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 34. Argentina Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 35. Rest of South America Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 36. Rest of South America Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 37. Rest of South America Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 38. Rest of South America Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 39. Asia Pacific Cancer Drug Therapy, by Country USD Million (2017-2022)
  • Table 40. Asia Pacific Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 41. Asia Pacific Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 42. Asia Pacific Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 43. Asia Pacific Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 44. China Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 45. China Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 46. China Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 47. China Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 48. Japan Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 49. Japan Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 50. Japan Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 51. Japan Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 52. India Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 53. India Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 54. India Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 55. India Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 56. South Korea Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 57. South Korea Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 58. South Korea Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 59. South Korea Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 60. Taiwan Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 61. Taiwan Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 62. Taiwan Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 63. Taiwan Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 64. Australia Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 65. Australia Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 66. Australia Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 67. Australia Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 71. Rest of Asia-Pacific Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 72. Europe Cancer Drug Therapy, by Country USD Million (2017-2022)
  • Table 73. Europe Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 74. Europe Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 75. Europe Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 76. Europe Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 77. Germany Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 78. Germany Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 79. Germany Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 80. Germany Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 81. France Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 82. France Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 83. France Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 84. France Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 85. Italy Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 86. Italy Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 87. Italy Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 88. Italy Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 89. United Kingdom Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 90. United Kingdom Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 91. United Kingdom Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 92. United Kingdom Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 93. Netherlands Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 94. Netherlands Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 95. Netherlands Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 96. Netherlands Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 97. Rest of Europe Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 98. Rest of Europe Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 99. Rest of Europe Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 100. Rest of Europe Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 101. MEA Cancer Drug Therapy, by Country USD Million (2017-2022)
  • Table 102. MEA Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 103. MEA Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 104. MEA Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 105. MEA Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 106. Middle East Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 107. Middle East Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 108. Middle East Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 109. Middle East Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 110. Africa Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 111. Africa Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 112. Africa Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 113. Africa Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 114. North America Cancer Drug Therapy, by Country USD Million (2017-2022)
  • Table 115. North America Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 116. North America Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 117. North America Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 118. North America Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 119. United States Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 120. United States Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 121. United States Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 122. United States Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 123. Canada Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 124. Canada Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 125. Canada Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 126. Canada Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 127. Mexico Cancer Drug Therapy, by Type USD Million (2017-2022)
  • Table 128. Mexico Cancer Drug Therapy, by Application USD Million (2017-2022)
  • Table 129. Mexico Cancer Drug Therapy, by End User USD Million (2017-2022)
  • Table 130. Mexico Cancer Drug Therapy, by Cancer USD Million (2017-2022)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Cancer Drug Therapy: by Type(USD Million)
  • Table 142. Cancer Drug Therapy Targeted Therapy , by Region USD Million (2023-2028)
  • Table 143. Cancer Drug Therapy Chemotherapy , by Region USD Million (2023-2028)
  • Table 144. Cancer Drug Therapy Immunotherapy , by Region USD Million (2023-2028)
  • Table 145. Cancer Drug Therapy: by Application(USD Million)
  • Table 146. Cancer Drug Therapy Angiogenesis Inhibitors , by Region USD Million (2023-2028)
  • Table 147. Cancer Drug Therapy MTOR Inhibitors , by Region USD Million (2023-2028)
  • Table 148. Cancer Drug Therapy Monoclonal Antibodies , by Region USD Million (2023-2028)
  • Table 149. Cancer Drug Therapy Cytokine Immunotherapy (IL-2) , by Region USD Million (2023-2028)
  • Table 150. Cancer Drug Therapy: by End User(USD Million)
  • Table 151. Cancer Drug Therapy Hospitals , by Region USD Million (2023-2028)
  • Table 152. Cancer Drug Therapy Clinics , by Region USD Million (2023-2028)
  • Table 153. Cancer Drug Therapy Other End Users , by Region USD Million (2023-2028)
  • Table 154. Cancer Drug Therapy: by Cancer(USD Million)
  • Table 155. Cancer Drug Therapy Blood Cancer , by Region USD Million (2023-2028)
  • Table 156. Cancer Drug Therapy Breast Cancer , by Region USD Million (2023-2028)
  • Table 157. Cancer Drug Therapy Prostate Cancer , by Region USD Million (2023-2028)
  • Table 158. Cancer Drug Therapy Gastrointestinal Cancer , by Region USD Million (2023-2028)
  • Table 159. Cancer Drug Therapy Gynecologic Cancer , by Region USD Million (2023-2028)
  • Table 160. Cancer Drug Therapy Respiratory/Lung Cancer , by Region USD Million (2023-2028)
  • Table 161. Cancer Drug Therapy Other Cancer Types , by Region USD Million (2023-2028)
  • Table 162. South America Cancer Drug Therapy, by Country USD Million (2023-2028)
  • Table 163. South America Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 164. South America Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 165. South America Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 166. South America Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 167. Brazil Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 168. Brazil Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 169. Brazil Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 170. Brazil Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 171. Argentina Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 172. Argentina Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 173. Argentina Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 174. Argentina Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 175. Rest of South America Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 176. Rest of South America Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 177. Rest of South America Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 178. Rest of South America Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 179. Asia Pacific Cancer Drug Therapy, by Country USD Million (2023-2028)
  • Table 180. Asia Pacific Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 181. Asia Pacific Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 182. Asia Pacific Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 183. Asia Pacific Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 184. China Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 185. China Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 186. China Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 187. China Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 188. Japan Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 189. Japan Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 190. Japan Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 191. Japan Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 192. India Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 193. India Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 194. India Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 195. India Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 196. South Korea Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 197. South Korea Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 198. South Korea Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 199. South Korea Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 200. Taiwan Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 201. Taiwan Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 202. Taiwan Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 203. Taiwan Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 204. Australia Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 205. Australia Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 206. Australia Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 207. Australia Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 209. Rest of Asia-Pacific Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 210. Rest of Asia-Pacific Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 211. Rest of Asia-Pacific Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 212. Europe Cancer Drug Therapy, by Country USD Million (2023-2028)
  • Table 213. Europe Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 214. Europe Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 215. Europe Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 216. Europe Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 217. Germany Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 218. Germany Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 219. Germany Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 220. Germany Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 221. France Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 222. France Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 223. France Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 224. France Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 225. Italy Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 226. Italy Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 227. Italy Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 228. Italy Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 229. United Kingdom Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 230. United Kingdom Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 231. United Kingdom Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 232. United Kingdom Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 233. Netherlands Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 234. Netherlands Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 235. Netherlands Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 236. Netherlands Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 237. Rest of Europe Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 238. Rest of Europe Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 239. Rest of Europe Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 240. Rest of Europe Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 241. MEA Cancer Drug Therapy, by Country USD Million (2023-2028)
  • Table 242. MEA Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 243. MEA Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 244. MEA Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 245. MEA Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 246. Middle East Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 247. Middle East Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 248. Middle East Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 249. Middle East Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 250. Africa Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 251. Africa Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 252. Africa Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 253. Africa Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 254. North America Cancer Drug Therapy, by Country USD Million (2023-2028)
  • Table 255. North America Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 256. North America Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 257. North America Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 258. North America Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 259. United States Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 260. United States Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 261. United States Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 262. United States Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 263. Canada Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 264. Canada Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 265. Canada Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 266. Canada Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 267. Mexico Cancer Drug Therapy, by Type USD Million (2023-2028)
  • Table 268. Mexico Cancer Drug Therapy, by Application USD Million (2023-2028)
  • Table 269. Mexico Cancer Drug Therapy, by End User USD Million (2023-2028)
  • Table 270. Mexico Cancer Drug Therapy, by Cancer USD Million (2023-2028)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Drug Therapy: by Type USD Million (2017-2022)
  • Figure 5. Global Cancer Drug Therapy: by Application USD Million (2017-2022)
  • Figure 6. Global Cancer Drug Therapy: by End User USD Million (2017-2022)
  • Figure 7. Global Cancer Drug Therapy: by Cancer USD Million (2017-2022)
  • Figure 8. South America Cancer Drug Therapy Share (%), by Country
  • Figure 9. Asia Pacific Cancer Drug Therapy Share (%), by Country
  • Figure 10. Europe Cancer Drug Therapy Share (%), by Country
  • Figure 11. MEA Cancer Drug Therapy Share (%), by Country
  • Figure 12. North America Cancer Drug Therapy Share (%), by Country
  • Figure 13. Global Cancer Drug Therapy share by Players 2022 (%)
  • Figure 14. Global Cancer Drug Therapy share by Players (Top 3) 2022(%)
  • Figure 15. Global Cancer Drug Therapy share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Amgen / Allergan (United States) Revenue, Net Income and Gross profit
  • Figure 18. Amgen / Allergan (United States) Revenue: by Geography 2022
  • Figure 19. Argos Therapeutics (Netherlands) Revenue, Net Income and Gross profit
  • Figure 20. Argos Therapeutics (Netherlands) Revenue: by Geography 2022
  • Figure 21. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 23. Aveo Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 24. Aveo Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 25. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer (Germany) Revenue: by Geography 2022
  • Figure 27. Exelixis (United States) Revenue, Net Income and Gross profit
  • Figure 28. Exelixis (United States) Revenue: by Geography 2022
  • Figure 29. Incyte (United States) Revenue, Net Income and Gross profit
  • Figure 30. Incyte (United States) Revenue: by Geography 2022
  • Figure 31. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck (United States) Revenue: by Geography 2022
  • Figure 33. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Roche (Switzerland) Revenue: by Geography 2022
  • Figure 35. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 37. Global Cancer Drug Therapy: by Type USD Million (2023-2028)
  • Figure 38. Global Cancer Drug Therapy: by Application USD Million (2023-2028)
  • Figure 39. Global Cancer Drug Therapy: by End User USD Million (2023-2028)
  • Figure 40. Global Cancer Drug Therapy: by Cancer USD Million (2023-2028)
  • Figure 41. South America Cancer Drug Therapy Share (%), by Country
  • Figure 42. Asia Pacific Cancer Drug Therapy Share (%), by Country
  • Figure 43. Europe Cancer Drug Therapy Share (%), by Country
  • Figure 44. MEA Cancer Drug Therapy Share (%), by Country
  • Figure 45. North America Cancer Drug Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Amgen / Allergan (United States)
  • Argos Therapeutics (Netherlands)
  • AstraZeneca (United Kingdom)
  • Aveo Pharmaceuticals (United States)
  • Bayer (Germany)
  • Exelixis (United States)
  • Incyte (United States)
  • Merck (United States)
  • Roche (Switzerland)
  • Bristol-Myers Squibb (United States)
Additional players considered in the study are as follows:
Eisai , Exelixis , Genentech (Roche) , Novartis , Pfizer , Prometheus Labs
Select User Access Type

Key Highlights of Report


May 2023 226 Pages 52 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Drug Therapy Quantitative research analysis
Global Cancer Drug Therapy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cancer Drug Therapy market are Amgen / Allergan (United States), Argos Therapeutics (Netherlands), AstraZeneca (United Kingdom), Aveo Pharmaceuticals (United States), Bayer (Germany), Exelixis (United States), Incyte (United States), Merck (United States), Roche (Switzerland) and Bristol-Myers Squibb (United States), to name a few.
is dominating the Cancer Drug Therapy Market.
"Lack of awareness" is seen as one of the major challenges by many Industry Players of Cancer Drug Therapy Market
The Cancer Drug Therapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Cancer Drug Therapy market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Cancer Drug Therapy Report?

Have a Query? Click Here

Other Related Reports

Internal Analgesic Tablet Comprehensive Study by Type (Central Painkiller, Narcotic Analgesics, Antispasmodic Painkillers, Anxiolytic Analgesics), Application (Home Use, Hospital, Clinic, Others), Di...
$ 3750
Essential Thrombocythemia Drug Comprehensive Study by Type (Givinostat, Idasanutlin, Pracinostat, Ruxolitinib Phosphate, Others), Application (Research Center, Hospital, Clinic, Others), Consumption ...
$ 3650
Neisseria Gonorrhoeae Infections Treatment Comprehensive Study by Type (Cribrostatin-6 , Dalbavancin , Debio-1453 , Gepotidacin Mesylate , Others), Patient Type (Gonorrhea treatment in adults, Gonorr...
$ 3750
Radiation Injury Drugs Comprehensive Study by Type (Aerosurf, BMX-001, C-2E2, C-2E5, Des-Asp Angiotensin 1, DG-3, Others), Application (Solar and Cosmic Radiation, Man-Made Radiation (Computed Tomogr...
$ 3750
Calcium Acetate Tablet Comprehensive Study by Sales Channel (Online, Offline), Packaging (Plastic Strip, Box, Small Bottle, Other), End User (Hospitals, Clinics, Dialysis Centres, Others) Players and...
$ 3500
Antibacterial Drug Resistance Comprehensive Study by Drugs (Antibiotics, Antifungals, Antivirals, Antimalarials, Anthelmintics, Others), Disease Type (Complicated Urinary Tract Infection (cUTI), Comp...
$ 3750